Language in Primary Progressive Aphasia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00537004|
Recruitment Status : Recruiting
First Posted : September 28, 2007
Last Update Posted : September 13, 2017
|Condition or disease|
|Primary Progressive Aphasia|
The Language in Primary Progressive Aphasia (PPA) aims to understand the behavioral, anatomical and physiological changes in people with PPA throughout the course of the illness. The researchers in this study want to increase awareness of PPA, educate others about this unique disorder, and to encourage more research to eventually develop therapies.
During the three-day research program, participants will be asked to undergo neuropsychological testing (paper and pencil tests that evaluate cognition), an MRI (a non-invasive brain-imaging procedure), an EEG (another non-invasive procedure that looks at brain waves when you think) and other computer and language testing batteries. Participants may be asked to return every two years to complete the same measures.
The study will recruit approximately 15 participants with PPA per year. For participants not living near Chicago, IL, flights and accommodations (for both the person with PPA and their companion) will be covered by the study.
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Official Title:||Language in Primary Progressive Aphasia|
|Study Start Date :||May 2007|
|Estimated Primary Completion Date :||April 2022|
|Estimated Study Completion Date :||April 2023|
PPA (Primary Progressive Aphasia)
Individuals with primary progressive aphasia
Individuals with no diagnosis of any type of dementia
- Neuropsychological variables [ Time Frame: Immediately after testing and at two years post-testing ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00537004
|Contact: Benjamin Raderemail@example.com|
|United States, Illinois|
|Chicago, Illinois, United States, 60611|
|Contact: Benjamin Rader 312-908-9681 firstname.lastname@example.org|
|Principal Investigator: M.-Marsel Mesulam, MD|
|Principal Investigator:||Marsel Mesulam, MD||Northwestern University Feinberg School of Medicine|